Head-to-head evidence
Atrasentan vs Zibotentan
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: Endothelin A receptor · full Chronic Kidney Disease pipeline
Atrasentan · Vanrafia
Marketed by Novartis
NCT01858532 · Phase 3 · terminated
This was a large, randomized, quadruple-blind, placebo-controlled trial in over 2,600 responder-enriched participants. Atrasentan significantly reduced serious kidney events, including doubling of creatinine and kidney failure, compared with placebo, meeting its primary endpoint with a hazard ratio of 0.654.
Next expected readout: April 2028 · NCT04573478 (registry estimate)
Zibotentan
Developed by AstraZeneca
NCT04724837 · Phase 2 · completed
Randomized, triple-blind, placebo-controlled phase 2 study with 447 participants in the analysis; the primary comparison (zibotentan 1.5 mg plus dapagliflozin vs dapagliflozin plus placebo) showed a statistically significant reduction in urinary albumin-to-creatinine ratio. Albuminuria is a regulator-accepted, disease-defining kidney endpoint, so the significant primary result in a well-designed controlled trial is strong evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Atrasentan's landscape · Zibotentan's landscape